Eledon pharmaceuticals reports fourth quarter and full year 2024 operating and financial results

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at massachusetts general hospital announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at uchicago medicine topline results from phase 2 bestow trial of tegoprubart in kidney transplantation expected in fourth quarter of 2025 proceeds from oversubscribed $85 million underwritten offering extend cash runway to end of 2026 irvine, calif., march 20, 2025 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today reported its fourth quarter and full year 2024 operating and financial results and reviewed recent business highlights.
ELDN Ratings Summary
ELDN Quant Ranking